Successful Reconstitution of Immunity in ADA-SCID by Stem Cell Gene Therapy Following Cessation of PEG-ADA and Use of Mild Preconditioning

This publication has 26 references indexed in Scilit:

• Cerebral Lymphoma in an Adenosine Deaminase–Deficient Patient With Severe Combined Immunodeficiency Receiving Polyethylene Glycol–Conjugated Adenosine Deaminase
  Pediatrics, 2005
• Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients
  European Journal of Immunology, 2005
• Long-term efficacy of enzyme replacement therapy for Adenosine deaminase (ADA)-deficient Severe Combined Immunodeficiency (SCID)
  Clinical Immunology, 2005
• Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates
  Nature Medicine, 2003
• Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99
  The Lancet, 2003
• Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial
  Blood, 2002
• Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement
  Nature Medicine, 2002
• Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA ⁻ Immunodeficient Patients
  Science, 1995
• Engraftment of gene–modified umbilical cord blood cells in neonates with adenosine deaminase deficiency
  Nature Medicine, 1995
• PEG-ADA: An alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency
  Human Mutation, 1995